FDA Approves Amneal's Denosumab Biosimilars for Bone Health
Amneal Pharmaceuticals and mAbxience announce FDA approval of Boncresa and Oziltus, biosimilar alternatives to Prolia and XGEVA for bone health treatment.
/ 4 items
#AMRX↓
FDA Approves Amneal’s New Epinephrine Injection Vials for Emergency Care
The FDA has approved Amneal Pharmaceuticals’ new single- and multi-dose epinephrine vials, expanding access to a critical emergency medicine used for allergic reactions and septic shock in hospitals and acute care settings.
Amneal's Generic Bimatoprost Ophthalmic Solution Approved by FDA
Amneal Pharmaceuticals has received FDA approval for a generic eye drop (bimatoprost 0.01%) used to treat high eye pressure linked to glaucoma and ocular hypertension.
FDA Approves Amneal's Affordable Narcolepsy Drug
Amneal Pharmaceuticals receives FDA approval for its generic sodium oxybate, offering a more accessible and cost-effective treatment for narcolepsy's excessive sleepiness and cataplexy in patients 7+.